8037 — China Biotech Services Holdings Income Statement
0.000.00%
Last trade - 00:00
- HK$274.52m
- HK$330.80m
- HK$211.99m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 59.2 | 656 | 624 | 1,852 | 212 |
Cost of Revenue | |||||
Gross Profit | 22.4 | 339 | 358 | 1,101 | 34.3 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 174 | 458 | 437 | 1,004 | 359 |
Operating Profit | -115 | 197 | 187 | 848 | -147 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -110 | 203 | 181 | 863 | -142 |
Provision for Income Taxes | |||||
Net Income After Taxes | -107 | 168 | 133 | 706 | -141 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -98.8 | 30.2 | 19.4 | 258 | -95.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -98.8 | 30.2 | 19.4 | 258 | -95.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.083 | 0.03 | 0.022 | 0.269 | -0.082 |
Dividends per Share |